Clinical note · #10
Office & outpatient
Patient: Mrs. Y · Age: 72
Presenting complaint: shortness of breath and lower extremity swelling
History of present illness
Mrs. Y, a 72-year-old female with known CHF and CKD, presents today for evaluation of progressively worsening shortness of breath and bilateral lower extremity swelling over the past week. She reports needing extra pillows at night and experiencing fatigue with minimal exertion. No fever, chest pain, or recent change in medications noted.
Review of systems
- Respiratory: dyspnea on exertion
- Cardiovascular: bilateral leg swelling
- General: fatigue
Past medical history
- Chronic systolic congestive heart failure
- Chronic kidney disease stage 3
- Hypertension
Physical examination
- General: mild respiratory distress
- CVS: S3 present, mild pedal edema
- Lungs: basal crackles bilaterally
Assessment
Decompensated chronic systolic heart failure in the setting of CKD stage 3. The presentation is consistent with fluid overload likely due to reduced cardiac output. Recent echocardiogram findings were reviewed and correlated clinically. The patient's renal function poses a limitation to aggressive diuresis; the physician considered alternative dosing strategies and potential need for adjunct therapy. Case discussion with cardiology guided the optimal management plan and next steps.
Plan (including documentation of consultant discussion)
- Increase furosemide dosage cautiously and monitor urine output and renal function.
- Repeat BMP and electrolyte panel in 48–72 hours to assess renal tolerance and potassium balance.
- Daily weight monitoring and sodium-restricted diet reinforced.
- Follow-up with cardiology within 1 week for medication titration and advanced heart failure management.
Discussion with Dr. Rahil, cardiologist: "Reviewed recent echocardiogram showing LVEF ~30% with moderate mitral regurgitation. Discussed patient's volume status and renal limitation to higher-dose diuretics. Agreed to increase furosemide to 40 mg BID, recheck BMP in 48 hours, and plan follow-up in 1 week to evaluate response and consider initiation of low-dose ARNI therapy."